Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Conditions:   Gastrointestinal Neoplasms;   Esophagogastric Junction Interventions:   Drug: Durvalumab;   Drug: FLOT chemotherapy Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials